In this edition, optimal antibiotics timing among inpatients with cancer; inflammation levels linked to survival in acute myeloid leukemia; dexrazoxane confers long-term cardioprotection for pediatric cancer and more. Read the full coverage here:

Optimal antibiotics timing ‘likely differs’ among inpatients with cancer, neutropenic fever

Inflammation levels linked to survival in acute myeloid leukemia

Dexrazoxane confers long-term cardioprotection after anthracyclines for pediatric cancer

Menin inhibitor produces high response rates in certain acute leukemia subtypes

Tisa-cel CAR-T reinfusion lacks durability for younger patients with B-cell ALL

References:

Chow EJ, et al. J Clin Oncol. 2023;doi:10.1200/JCO.22.02423.

Issa GC, et al. Nature. 2023;doi:10.1038/s41586-023-05812-3.

Krupski C, et al. Abstract LBA4. Presented at: Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Feb. 15-19, 2023; Orlando.

Lasry A, et al. Nat Cancer. 2022;doi:10.1038/s43018-022-00480-0. Villars J, et al. Am J Med Qual. 2023;doi:10.1097/JMQ.0000000000000093.